WVE-006
- Generic Name
- WVE-006
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants with Pi*ZZ AATD
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06405633
- Locations
- 🇦🇺
St. Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
🇨🇦Dalhousie University - Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
🇳🇿Waikato Hospital, Hamilton, New Zealand
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Wave Life Sciences Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT06186492
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology,, Merthyr Tydfil, Wales, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath